[1]
|
Jia, W., Weng, J., Zhu, D., et al. (2019) Standards of Medical Care for Type 2 Diabetes in China 2019. Diabetes/Metabolism Research and Reviews, 35, e3158. https://doi.org/10.1002/dmrr.3158
|
[2]
|
Targher, G., Bertolini, L., Padovani, R., et al. (2007) Prevalence of Nonalcoholic Fatty Liver Disease and Its Association with Cardiovascular Disease among Type 2 Diabetic Patients. Diabetes Care, 30, 1212-1218.
https://doi.org/10.2337/dc06-2247
|
[3]
|
Adams, L., Waters, O., Knuiman, M., et al. (2009) NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-Up Study. The American Journal of Gastroenterology, 104, 861-867.
https://doi.org/10.1038/ajg.2009.67
|
[4]
|
Peng, L., Wu, S., Zhou, N., et al. (2021) Clinical Characteristics and Risk Factors of Nonalcoholic Fatty Liver Disease in Children with Obesity. BMC Pediatrics, 21, 122. https://doi.org/10.1186/s12887-021-02595-2
|
[5]
|
Ipsen, D., Lykkesfeldt, J., Tveden-Nyborg, P.J.C., et al. (2018) Molecular Mechanisms of Hepatic Lipid Accumulation in Non-Alcoholic Fatty Liver Disease. Cellular and Molecular Life Sciences, 75, 3313-3327.
https://doi.org/10.1007/s00018-018-2860-6
|
[6]
|
Mantovani, A. and Dalbeni, A. (2021) Treatments for NAFLD: State of Art. International Journal of Molecular Sciences, 22, 2350. https://doi.org/10.3390/ijms22052350
|
[7]
|
Hazlehurst, J., Woods, C., Marjot, T., et al. (2016) Non-Alcoholic Fatty Liver Disease and Diabetes. Metabolism, 65, 1096-1108. https://doi.org/10.1016/j.metabol.2016.01.001
|
[8]
|
Samuel, V. and Shulman, G.J. (2018) Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metabolism, 27, 22-41. https://doi.org/10.1016/j.cmet.2017.08.002
|
[9]
|
Engin, A. (2017) Non-Alcoholic Fatty Liver Disease. Advances in Experimental Medicine and Biology, 960, 443-467.
https://doi.org/10.1007/978-3-319-48382-5_19
|
[10]
|
Ercin, C., Dogru, T., Genc, H., et al. (2015) Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 13, 319-325. https://doi.org/10.1089/met.2015.0018
|
[11]
|
Hwang, J., Stein, D., Barzilai, N., et al. (2007) Increased Intrahepatic Triglyceride Is Associated with Peripheral Insulin Resistance: In Vivo MR Imaging and Spectroscopy Studies. American Journal of Physiology-Endocrinology and Metabolism, 293, E1663-E1669. https://doi.org/10.1152/ajpendo.00590.2006
|
[12]
|
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 中国非酒精性脂肪性肝病诊疗指南(2010年修订版) [J]. 中国医学前沿杂志(电子版), 2012, 4(7): 4-10.
|
[13]
|
Landreh, M., Johansson, J., Jörnvall, H., et al. (2013) C-Peptide: A Molecule Balancing Insulin States in Secretion and Diabetes-Associated Depository Conditions. Hormone and Metabolic Research, 45, 769-773.
https://doi.org/10.1055/s-0033-1347208
|
[14]
|
Zhao, L., Ma, J., Wang, S., et al. (2015) Relationship between β-Cell Function, Metabolic Control, and Microvascular Complications in Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics, 17, 29-34.
https://doi.org/10.1089/dia.2014.0214
|
[15]
|
Chen, M., Li, T., Zhang, R., et al. (2015) Clinical Features of Non-Alcoholic Fatty Liver Disease and Its Relationship with Serum C-Peptide Levels in Patients with Latent Autoimmune Diabetes in Adults. Chinese Medical Journal, 95, 3575-3578.
|
[16]
|
Tricò, D., Caprio, S., Rosaria Umano, G., et al. (2018) Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings from a Multiethnic Cohort. Hepatology, 68, 1376-1390. https://doi.org/10.1002/hep.30035
|
[17]
|
Atsawarungruangkit, A., Chenbhanich, J. and Dickstein, G. (2018) C-Peptide as a Key Risk Factor for Non-Alcoholic Fatty Liver Disease in the United States Population. World Journal of Gastroenterology, 24, 3663-3670.
https://doi.org/10.3748/wjg.v24.i32.3663
|
[18]
|
王建, 陈红. C肽在糖尿病慢性并发症发生和发展中的作用及其机制[J]. 中华内分泌代谢杂志, 2008, 24(4): 463-464.
|
[19]
|
Yaribeygi, H., Maleki, M., Sathyapalan, T., et al. (2019) The Effect of C-Peptide on Diabetic Nephropathy: A Review of Molecular Mechanisms. Life Sciences, 237, Article ID: 116950. https://doi.org/10.1016/j.lfs.2019.116950
|
[20]
|
Janowska, J., Chudek, J., Olszanecka-Glinianowicz, M., et al. (2016) Interdependencies among Selected Pro-Inflammatory Markers of Endothelial Dysfunction, C-Peptide, Anti-Inflammatory Interleukin-10 and Glucose Metabolism Disturbance in Obese Women. International Journal of Medical Sciences, 13, 490-499. https://doi.org/10.7150/ijms.14110
|
[21]
|
Marx, N., Walcher, D., Raichle, C., et al. (2004) C-Peptide Colocalizes with Macrophages in Early Arteriosclerotic Lesions of Diabetic Subjects and Induces Monocyte Chemotaxis in Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 540-545. https://doi.org/10.1161/01.ATV.0000116027.81513.68
|
[22]
|
Li, W., Huang, E. and Gao, S. (2017) Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review. Journal of Alzheimer’s Disease, 57, 29-36. https://doi.org/10.3233/JAD-161250
|
[23]
|
Tang, A., Rabasa-Lhoret, R., Castel, H., et al. (2015) Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients with Type 2 Diabetes: A Randomized Trial. Diabetes Care, 38, 1339-1346. https://doi.org/10.2337/dc14-2548
|